Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy

NCT01990534 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01990534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01990534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 14, 2014
Completion date
March 12, 2020
Enrollment
60 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma